Document:

​

Exhibit 10.17
​
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED.
​
SECOND AMENDMENT TO LICENSE AGREEMENT
​
This Second Amendment to License Agreement (“AMENDMENT”), is entered into as of the ___ of July, 2020 (“EFFECTIVE DATE”), by and among Thomas Jefferson University (“TJU”) and Immunome, Inc. (“COMPANY”) (collectively, the “Parties”).
​
WHEREAS the Parties have entered into an Exclusive License Agreement with an effective date of the 1st of June, 2012, as amended by the First Amendment to the License Agreement, dated  October 19, 2017, (the Exclusive License Agreement, as so amended, the “LICENSE AGREEMENT”);
​
WHEREAS, the Parties desire to modify certain terms of the License Agreement as set forth in this Amendment; and
​
WHEREAS, any capitalized term not separately defined in this Amendment shall have the meaning ascribed to it in the License Agreement.
​
NOW, THEREFORE, in consideration of the terms and conditions set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, the parties hereto agree as follows:
​
1.   Amendments.  Section 4.3 of the License Agreement is amended and restated in its entirety as follows:
​
4.3  (a) Except as provided in Section 4.3(c), LICENSEE shall pay to TJU during the term of this Agreement a royalty of [***] of NET SALES by LICENSEE and SUBLICENSEES in any countries where there is a VALID CLAIM; and
​
(b) Except as provided in Section 4.3(c), LICENSEE shall pay to TJU during the term of this Agreement a royalty of [***] of NET SALES by LICENSEE and SUBLICENSEES in any countries where there is no VALID CLAIM.
​
(c) The royalty for NET SALES of LICENSED PRODUCTS or LICENSED PROCESSES by a SUBLICENSEE under an agreement between LICENSEE and such SUBLICENSEE entered into before CLINICAL PROOF OF CONCEPT (as defined below for such LICENSED PRODUCT or LICENSED PROCESS (“OTHER NET SALES”) shall be [***] of the royalty actually paid by the SUBLICENSEE to LICENSEE; provided that such agreement between COMPANY and such SUBLICENSEE provides for a [***] or less percentage royalty on net sales of such LICENSED PRODUCT and/or LICENSED PROCESS to be paid to COMPANY by SUBLICENSEE.  Where such agreement provides for more than a [***] royalty, then the provisions of Sections 4.3(a) and (b) shall
​

​
SECOND AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
Page 1 of 3

​

apply. Where such agreement provides for a [***] or less royalty and a royalty that exceeds [***] (e.g., a scaled royalty based on the amount of net sales), then the provisions of this Section 4.3(c) shall apply for the royalties that are [***] or below and the provisions of Sections 4.3(a) and (b) shall apply for the royalties that exceed [***].
​
For purposes of calculating the royalties under Sections 4.3(a) and (b), where royalties on OTHER NET SALES are paid under this Section 4.3(c), then such OTHER NET SALES shall be disregarded and excluded from the definition of NET SALES.
​
Notwithstanding the foregoing, in any sublicense of a LICENSED PRODUCT or LICENSED PROCESS, if COMPANY or an AFFILIATE also grants rights to other licensed products or patents owned or controlled by [***] and name [***] as an inventor and are necessary for the use or sale of the LICENSED PRODUCT or LICENSED PROCESS by such SUBLICENSEE, the modified royalty due on OTHER NET SALES provided under this Section 4(c) shall only take effect if [***] also agrees to a comparable reduction of the percentage of the total amount of royalty it is to receive on such sales. Should [***] not agree in writing to such comparable reduction then the royalty due on such NET SALES of LICENSED PRODUCT or LICENSED PROCESS by a SUBLICENSEE will be calculated as per Sections 4.3(a) and 4.3(b).
​
For the purposes of this SECTION 4.3(c) “CLINICAL PROOF OF CONCEPT” shall mean the completion of the first clinical trial in patients with respect to the applicable LICENSED PRODUCT or LICENSED PROCESS.
​
2.   Term of Amendment. This Amendment shall be in effect from the Effective Date and shall continue for the term of the License Agreement.
​
3.   Full Force and Effect. Except as specifically modified or amended by the terms of this Amendment, the License Agreement and all provisions contained therein are, and shall continue, in full force and effect and are hereby ratified and confirmed.
​
4.   Integration. The Agreement, as amended by this Amendment, contains the entire agreement of the parties with regard to this Amendment and the Agreement, and supersedes and replaces any prior agreements as to that matter. Neither this Amendment nor the Agreement may be changed or modified, in whole or in part, except by an instrument in writing signed by TJU and Company.
​
​

​
SECOND AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
Page 2 of 3

​

5.   Counterparts. This Amendment may be executed in any number of separate counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.
​
6.   Miscellaneous. This Amendment shall be binding upon all the parties to the License Agreement and their respective successors and assigns.
​
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.
​
	Agreed:
	​

	​

	THOMAS JEFFERSON UNIVERSITY
	​

	​

	Name:
	Rose Ritts, PhD
	​

	Title:
	Executive Vice President and Chief Innovation Officer
	​

	​

	Signature:
	/s/ Rose Ritts
	​
	​

​
	IMMUNOME, INC.
	​

	​

	Name:
	Purnanand Sarma
	​

	Title:
	President & CEO
	​

	​

	Signature:
	/s/ Purnanand D Sarma
	​
	​

​

​
SECOND AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
Page 3 of 3Exhibit
10.1

 

November
16, 2020

 

NewAge,
Inc.

2420
17th Street, Suite 220

Denver,
Colorado 80202

 

	 	Re:	Amended
    and Restated Agreement and Plan of Merger dated September 30, 2020

 

Ladies
and Gentlemen:

 

This
letter agreement (this “Agreement”) is made by the undersigned under the Amended and Restated Agreement and
Plan of Merger dated September 30, 2020 (the “Merger Agreement”), by and among NewAge, Inc., a Washington corporation
(“Parent”), Ariel Merger Sub, LLC, a Utah limited liability company, Ariel Merger Sub 2, LLC, a Utah limited
liability company, Ariix, LLC, a Utah limited liability company (the “Company”), the “Sellers”
identified therein, and Frederick W. Cooper solely in his capacity as Sellers Agent thereunder (“Sellers Agent”).
This Agreement waives certain provisions in and amends the Merger Agreement. Capitalized terms used but not defined in this Agreement
have the respective meanings set forth in the Merger Agreement.

 

	1.	Closing
    Cash Consideration. The Company, the Sellers, and Sellers Agent hereby waive payment of the Merger Consideration under
    the Merger Agreement, including the payment of the Closing Cash Consideration and the Closing Stock Consideration at Closing.
    In lieu thereof,
	 	 	 
	 	a.	Parent
    shall pay $10,000,000 to the Members by wire transfer of immediately available funds in the amounts and to the accounts set
    forth on the Payment Schedule within two Business Days of the later of (x) the date Sellers and the Company satisfy the conditions
    in Section 7.2(e) and (f) of the Merger Agreement, except that the interim financial statements under Section 7.2(f)(1) of
    the Merger Agreement will be for the nine months ended September 30, 2020 (the “Financial Statements Delivery Date”)
    and (y) the date Parent repays its credit facility with East West Bank.
	 	 	 
	 	b.	On
    the date hereof, in addition to the Closing Stock Consideration issuable under Section 2.4(a) of the Merger Agreement, Parent
    shall issue and deliver to certain Members, 3,703,703 shares of Common Stock (the “Additional Closing Shares”),
    as determined in accordance with the Payment Schedule, free and clear of all Encumbrances (other than those arising under
    securities Laws and under the Lock-Up Letter). “Closing Stock Consideration” means 16,000,000 shares of
    Common Stock.

 

    	 

     

    

 

	 	c.	On
    the date that is 30 days after Shareholder Approval, in addition to the Thirty-Day Stock Consideration issuable under Section
    2.4(c) of the Merger Agreement and the Severance Stock issuable under Section 5.13 of the Merger Agreement, Parent shall issue
    and deliver to certain Members, 3,000,000 shares of Common Stock (the “Additional Thirty-Day Stock Consideration”),
    as determined in accordance with the Payment Schedule, free and clear of all Encumbrances (other than those arising under
    securities Laws and under the Lock-Up Letter). “Stock Consideration” means 58,103,703 shares of Common
    Stock, subject to adjustment, comprising the Closing Stock Consideration, the Additional Closing Shares, the Thirty-Day Stock
    Consideration, the additional Thirty-Day Stock Consideration, and First Anniversary Stock Consideration Payments.
	 	 	 
	 	d.	On
    the six month anniversary of the Closing, Parent shall pay or cause to be paid the Six-Month Anniversary Cash Consideration
    as described in Section 2.4(b) and as adjusted under Section 2.5 of the Merger Agreement.
	 	 	 
	 	e.	Registration
    Rights. Within 30 days after the Financial Statements Delivery Date and the filing by Parent of the Current Report on
    Form 8-K/A containing the financial statements, Parent shall prepare and file (at Parent’s expense) a Registration Statement
    on Form S-3 with the Securities and Exchange Commission covering the resale of the Additional Closing Shares. Each Seller
    holding Additional Closing Shares shall furnish to the Parent such information regarding itself, the securities held by it,
    and the intended method of disposition of such Additional Closing Shares as is reasonably required to effect the registration
    of the resale of such Seller’s Additional Closing Shares.
	 	 	 
	2.	Closing
    Deliveries and Closing Conditions. The Company and Sellers have not satisfied certain of their conditions to Closing in
    the Merger Agreement, including those in Section 6.1(d), (e), (f), (g), (h), and (l) and Section 7.2(e) and (f) (collectively,
    the “Conditions”).
	 	 	 
	3.	Waiver.
    For the limited purpose of Closing, Parent waives performance of the Conditions.
	 	 	 
	4.	Continued
    Obligation to Perform. Following the Closing, the Sellers shall use their best efforts (including the expenditure of fees
    and expenses and cooperating with the Company and Parent) to satisfy the Conditions as quickly as possible.
	 	 	 
	5.	Indemnification.
	 	 	 
	 	a.	In
    addition to the indemnification obligations under the Merger Agreement, Sellers shall indemnify, defend, and hold harmless
    Parent and their Other Indemnified Persons from and against all Losses and shall pay to Parent and their Other Indemnified
    Persons the amount of such Losses to the extent arising or resulting from, related to, or in connection with, the failure
    to satisfy the Conditions as of Closing or failure to comply with Section 4 of this Agreement. For the avoidance of doubt,
    Sellers shall indemnify, defend, and hold harmless Parent and their Other Indemnified Persons from and against all Losses
    arising or resulting from, related to, or in connection with any breach, termination or dispute arising under any of the contracts
    identified on Exhibit 6.1(d) of the Merger Agreement due to a failure by Sellers or the Company to obtain consents for such
    contracts.

 

    	2

     

    

 

	 	b.	This
    Section 5 is not subject to the limitations in Section 8.6 of the Merger Agreement.
	 	 	 
	 	c.	Sellers
    are not obligated to indemnify, defend, or hold harmless Parent or their Other Indemnified Persons from and against any Losses
    arising or resulting from a default under the Company’s loan with Bank of America under the Paycheck Protection Program
    to the extent such Losses constitute current liabilities of the Company used in calculating Closing Working Capital.
	 	 	 
	6.	Amendment
    and Modification, Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed
    by the parties hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth
    in writing and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or
    delay in exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a
    waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other
    or further exercise thereof or the exercise of any other right, remedy, power or privilege.
	 	 	 
	7.	Effectiveness
    of this Agreement. Notwithstanding the earlier execution and delivery of this Agreement the effectiveness of this Agreement
    is conditioned on the Closing of the transactions contemplated by the Merger Agreement. If the Closing shall occur, this Agreement
    shall become effective concurrently with the Closing on the Closing Date. If the Merger Agreement is terminated for any reason
    in accordance therewith this Agreement shall be null and void ab initio.

 

    	3

     

    

 

Very
truly yours,

 

	/s/ Frederick Cooper	 
	Frederick Cooper, as Sellers Agent	 
	 	 	 
	ARIIX,
    LLC	 
	 	 	 
	By:
    	/s/
    Frederick Cooper	 
	Name:
    	Frederick Cooper	 
	Its:	Manager	 
	 	 	 
	By:
    	/s/
    Jeffrey Yates	 
	Name:
    	Jeffrey Yates	 
	Its:	Manager	 
	 	 	 
	By:
    	/s/
    Riley Timmer	 
	Name:
    	Riley Timmer	 
	Its:	Manager	 
	 	 	 
	Accepted
    and agreed:	 
	 	 	 
	NEWAGE,
    INC.	 
	 	 	 
	By:
    	/s/
    Brent Willis	 
	Name:
    	Brent
    Willis	 
	Its:	Chief
    Executive Officer	 

 

Signature
Page to Waiver Letter

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]